

# Management of chronic pain with *Jalaprakshalana* (water-wash) *Shodhita* (processed) *Bhanga* (*Cannabis sativa* L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial

Swagata Dilip Tavhare, Rabinarayan Acharya<sup>1</sup>, R. Govind Reddy<sup>2</sup>, Kartar Singh Dhiman<sup>3</sup>

Department of Dravyaguna, GJ Patel Institute of Ayurvedic Studies and Research, New Vallabhvidyanagar, Anand, <sup>1</sup>Department of Dravyaguna, Institute for Post Graduate Teaching and Research in Ayurved, Gujarat Ayurved University, Jamnagar, Gujarat, <sup>2</sup>Regional Ayurveda Research Institute for Mother and Child Health, CCRAS, Nagpur, Maharashtra, <sup>3</sup>Central Council for Research in Ayurvedic Sciences, Ministry of AYUSH, Government of India, New Delhi, India

## Abstract

**Introduction:** Pain is a common and complex symptom of cancer having physical, social, spiritual and psychological aspects. Approximately 70%–80% of cancer patients experiences pain, as reported in India. Ayurveda recommends use of *Shodhita* (Processed) *Bhanga* (*Cannabis*) for the management of pain but no research yet carried out on its clinical effectiveness. **Objective:** To assess the analgesic potential of *Jalaprakshalana* (Water-wash) processed *Cannabis sativa* L. leaves powder in cancer patients with deprived quality of life (QOL) through openlabel single arm clinical trial. **Materials and Methods:** Waterwash processed Cannabis leaves powder filled in capsule, was administered in 24 cancer patients with deprived QOL presenting complaints of pain, anxiety or depression; for a period of 4 weeks; in a dose of 250 mg thrice a day; along with 50 ml of cow's milk and 4 g of crystal sugar. Primary outcome i.e. pain was measured by Wong-Bakers FACES Pain Scale (FACES), Objective Pain Assessment (OPA) scale and Neuropathic Pain Scale (NPS). Secondary outcome namely anxiety was quantified by Hospital Anxiety and Depression Scale (HADS), QOL by FACT-G scale, performance score by Eastern Cooperative Oncology Group (ECOG) and Karnofsky score. **Results:** Significant reduction in pain was found on FACES Pain Scale ( $P < 0.05$ ), OPA ( $P < 0.05$ ), NPS ( $P < 0.001$ ), HADS ( $P < 0.001$ ), FACT-G scale ( $P < 0.001$ ), performance status score like ECOG ( $P < 0.05$ ) and Karnofsky score ( $P < 0.01$ ). **Conclusion:** *Jalaprakshalana Shodhita Bhanga* powder in a dose of 250 mg thrice per day; relieves cancerinduced pain, anxiety and depression significantly and does not cause any major adverse effect and withdrawal symptoms during trial period.

**Keywords:** Anxiety, *Bhanga*, *Cannabis sativa*, cancer pain, depression, quality of life, *Shodhana*

## Introduction

Despite all advancements in prevention, early detection, with newer and more effective treatment modalities, cancer remains one of the most debilitating and deadly diseases and is second leading cause of mortality.<sup>[1]</sup> Sheer potential of suffering from cancer can be a horrifying experience for anyone bearing this diagnosis, while 'pain' is probably one of the most frightening symptom of cancers which usually intensifies as the disease progresses in 50%–70% patients.<sup>[2]</sup> Less than half of patients get adequate relief of pain, which negatively impacts their quality of life (QOL).<sup>[3]</sup> Generally, pain is a subjective feeling that has not till date been easily and universally quantified.<sup>[4]</sup>

Patients with similar cancer types may experience different intensities of pain. Current WHO ladder method consistently failed to provide sufficient relief to 10%–20% of advanced cancer patients with pain and reported side effects of analgesics are the reasons for concern over these symptoms.<sup>[5]</sup> *Bhanga*

**Address for correspondence:** Dr. Swagata Dilip Tavhare, Room 422, First Floor, Department of Dravyaguna, GJ Patel Institute of Ayurvedic Studies and Research, New Vallabhvidyanagar, Anand- 388121, Gujarat, India. E-mail: drswagata32@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Tavhare SD, Acharya R, Reddy RG, Dhiman KS. Management of chronic pain with *Jalaprakshalana* (water-wash) *Shodhita* (processed) *Bhanga* (*Cannabis sativa* L.) in cancer patients with deprived quality of life: An open-label single arm clinical trial. AYU 2019;40:34-43.

### Access this article online

#### Quick Response Code:



**Website:**  
[www.ayujournal.org](http://www.ayujournal.org)

**DOI:**  
10.4103/ayu.AYU\_43\_19

(*Cannabis*) is a potent analgesic reported by folklore, Ayurveda as well as modern medical science and researches.<sup>[6]</sup> If used in *Ashodhita* (Unprocessed) form, may cause *Madakari* (Intoxicant) effects hence, Ayurveda classics have advised *Shodhana* (Purifying process) of *Bhanga* before its therapeutic use.<sup>[7]</sup> *Cannabis* leaves processed with water-wash method has been advised for the management of pain.<sup>[8,9]</sup> As per 'The 1961 Convention', due to inclusion under narcotic category,<sup>[10]</sup> therapeutic as well as research use of *Cannabis* was stopped. In 19<sup>th</sup> century, again, the drug started gaining scientific attraction due to its significant therapeutic effects in palliative oncology care; as concurrent use of morphine is reported to causes many ill effects.<sup>[11]</sup> Various researches report positive results of *Cannabis* in managing symptoms cluster developed in cancer patients.

### Objective

To assess the clinical effectiveness of water-wash processed *Cannabis* leaves powder in cancer patients having complaints of pain, anxiety, depression and deprived QOL.

### Material

#### Preparation of trial drug (TD) by *Jalaprakshalana* (Water-wash) processing method

Leaves of female species of *Cannabis sativa* L. were tied in a muslin cloth; washed with water till greenish color stops oozing out from leaves, later shade dried,<sup>[12,13]</sup> finely powdered with mixer grinder and filled in red and white hard gelatine capsule of size "0" and dimension  $21.04 \pm 0.4$  having capacity of 250 mg. Patients were selected by 'purposive sampling' (Non-random) method from outpatient department and in patient department section of Raja Ramdeo Anandilal Podar, Central Ayurveda Research Institute for Cancer (RRAP-CARIC), Worli, Mumbai; irrespective of specific region, religion country.

### Selection of patients

#### Inclusion criteria

Clinically diagnosed patients of all type of cancer; irrespective of their gender; between age 18 to 70 years; who were receiving possible available treatment(s) for the management of cancer or terminally ill patients with any Eastern Cooperative Oncology Group (ECOG) score; presenting 'pain' as a chief symptom and willing to participate in clinical trial after getting information about drug and treatment protocol were included.

#### Exclusion criteria

Patients suffering from systemic diseases such as uncontrolled hypertension/diabetes, cardiac/pulmonary/hepatic or renal dysfunctions, HIV/VDRL, pregnant or breast-feeding women, patients with inability to comprehend and complete proposed course of intervention were excluded.

### Ethical and legal approval

The study was approved by the Institutional Ethics Committee of IPGT and RA, Gujarat Ayurved University, Jamnagar (PGT/7/-A/ethics/2015-16/2625) and RRAP, CARIC, CCRAS,

Worli, Mumbai (CARIC/Ref. No. 03/16-17). 'Clinical Research Proforma' (CRP) was designed exclusively for cancer palliative care focusing on patient's symptoms and related details. 'Patient's consent form' (according to the guidelines of the CCRAS) and 'drug compliance form' was developed which was presented and approved through IEC-CARIC and Departmental Research Committee meeting at IPGT and RA, Jamnagar. Trial drug was procured through the pharmacy of Gujarat Ayurved University, Jamnagar after taking due approval of the state excise authority. Records were maintained as per the present rules and regulations.

### Trial registration

Study was registered in Clinical Trials Registry of India. (CTRI/2016/02/006658).

### Methods

#### Study design

An open labelled single arm clinical trial of sample size 40 (Dropout rate of 25%) was conducted at RRA Podar CARIC, CCRAS, Worli, Mumbai, of duration 1 month with four follow-up at interval of a week and last one follow-up for assessment of withdrawal symptoms after trial drug was stopped. Before treatment (BT) and after treatment (AT), laboratory investigations namely complete blood count, urine test, biochemistry parameters such as total- direct- indirect bilirubin, albumin: globulin ratio, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, triglycerides, total cholesterol (TC), high-density lipoproteins (HDL), low-density lipoproteins (LDL), very LDL, TC: HDL ratio, serum urea, serum uric acid, serum creatinine, fasting and post prandial blood sugar level and ECG were done to check the safety aspects after 1 month of administration of trial drug and to check any biochemical parameter disturbance after TD administration. Recommended dose of water-wash processed cannabis leaves as per Ayurvedic pharmacopoeia of India is 250 mg<sup>[14]</sup> which was given to patients thrice a day (9 am, 3 pm and 9 pm) orally with 50 ml of cow's milk mixed with 4 g of crystal sugar as an adjuvant; for the period of 4 weeks. Patients were asked to discontinue any type of analgesic drug during trial period. However if patient had intolerable pain, then they were advised to inform and report trial center or nearby clinic and rescue medicine advice was kept in protocol. Patients were given 'drug compliance form' to fill the details of consumption of medicine capsules.

Telephonic follow-up was maintained with patients who failed to attend follow-up every week due to continuation of their chemotherapy or radiation cycles or due to long distance as some patients in trial were from other states.

### Case report form

Data filled in 'Case Report Form' (CRF) was also entered in electronic format designed in Microsoft Excel. After trial completion, CRFs along with laboratory investigations reports were submitted to IEC for evaluation.

### Outcome measures

For assessment of pain, Wong -Baker FACES Pain Rating Scale for pain (FACES),<sup>[15]</sup> Objective Pain Assessment (OPA)<sup>[16]</sup> and Neuropathic Pain Scale (NPS) were used.<sup>[17]</sup> Anxiety and depression were assessed by Hospital Anxiety and Depression Scale (HADS).<sup>[18]</sup> Associated complaint's scoring was evaluated by WHO-DFC project guidelines for developing clinical research methodology in Ayurveda.<sup>[19]</sup> For estimation of QOL in cancer patients, FACT-G scale was adopted.<sup>[20]</sup> Performance status of a cancer patient was evaluated by ECOG and Karnofsky score.<sup>[21]</sup> All the above parameters scorings were recorded at baseline and after every week of assessment. 'Post withdrawal effects assessment scale'<sup>[22]</sup> and 'adverse drug reaction (ADR) reporting forms' were noted at the end of 5<sup>th</sup> week.

### Statistical analysis

Obtained data were analyzed statistically using SigmaStat 3.5 version for Windows (Systat Software, Inc., 501 Canal Blvd., Suite E, Point Richmond, California). Statistical analysis was done by applying 'paired t-test' to BT and AT assessment scores.  $P < 0.05$  was considered statistically significant.<sup>[23]</sup> Percentage difference of change in relief of each symptom at every week period to achieve 50% relief in respective symptom was calculated. Overall improvement in signs and symptoms. Percentage improvement of every symptom per week for each patient was calculated by the formula (Before Treatment value -After Treatment value)/Before Treatment value  $\times 100$ . Average of the percentage improvement was calculated. of the percentage improvement was calculated. Obtained results were measured according to the grades as cure/complete remission  $75\% \geq 100\%$ , marked Improvement  $51\% \geq 74\%$ , moderate improvement  $26\% - 50\%$ , mild Improvement  $1\% \geq 25\%$  and unchanged 0%.

## Observations and Results

### Status of enrolled patients

Total 37 (100%) patients were enrolled in trial out of which 24 (64.86%) have completed treatment while 13 (35.14%) patients dropped out due to reasons such as conventional therapy settings and inconvenience in long distance travelling to reach trial center.

### Demographic profile


Demographic data of enrolled patients ( $n = 37$ ) viz. distribution of patients according to age, gender, marital status, educational status, past and present occupation, habitat and religion are depicted in Table 1.

### Treatment modalities opted by patients for symptoms management

Conventional treatment like chemotherapy and radiation therapy were received (ing) by 40.54% and 18.92% patients respectively whereas 37.83% patients were undergoing treatment from Complementary and Alternative Medicine pathies and 40.54% patients were found suffering from various side effects of conventional treatment for cancer.

**Table 1: Demographic profile of enrolled patients**

| Data               | Criteria            | n (n=37) | Percentage |
|--------------------|---------------------|----------|------------|
| Age                | 18-70               | 37       | 100        |
| Gender             | Male                | 15       | 40.54      |
|                    | Female              | 22       | 59.46      |
| Marrital status    | Married             | 22       | 59.46      |
|                    | Unmarried           | 7        | 18.92      |
|                    | Widow/r             | 8        | 21.62      |
|                    | Divorcee            | 0        | 0          |
|                    | Illiterate          | 7        | 18.92      |
| Educational status | Read/write/educated | 30       | 81.08      |
|                    | Desk                | 12       | 32.43      |
| Past occupation    | Field               | 0        | 0          |
|                    | Field + labour      | 6        | 16.22      |
|                    | Housewife           | 12       | 32.43      |
|                    | Business            | 5        | 13.51      |
|                    | Student             | 1        | 2.70       |
|                    | Other               | 1        | 2.70       |
|                    | Desk                | 7        | 18.92      |
| Present occupation | Field               | 0        | 0          |
|                    | Labour              | 0        | 0          |
|                    | Housewife           | 18       | 48.65      |
|                    | Business            | 5        | 13.51      |
|                    | Student             | 1        | 2.7        |
| Habitat            | Other               | 6        | 16.22      |
|                    | Urban               | 22       | 59.46      |
|                    | Semi-urban          | 11       | 29.73      |
|                    | Rural               | 4        | 10.81      |
| Religion           | Hindu               | 36       | 97.30      |
|                    | Christian           | 1        | 2.70       |



**Graph 1:** Cancer of: breast (16.21%), buccal mucosa (13.51%), cervix (8.10%) and oesophagus, lung, adenocarcinoma, ovary, colon, lung with pancost, sarcoma, ewings sarcoma, retroperitoneal mass lesion with multiple pulmonary and hepatic metastasis, squamous cell carcinoma, giant cell tumor, palate, brain, adenocarcinoma, rectum-anal canal, bone, tongue (In sequence)

### Distribution of patients according to types of cancer

Patients presenting ‘pain’ as chief complaint having various nineteen different types of cancer are depicted in Graph 1, out of which cancer of breast (16.21%), buccal mucosa (13.51%), cervix (8.10%) and esophagus (8.10%) were found in most patients.

### Chief and associated complaints (n = 24)

Pain (100%) was the chief complaint presented by all patients followed by anxiety (79.17%), depression (83.33%), fatigue (70.83%), exhaustion (62.5%), loss of appetite (54.17%), insomnia (45.83%), tastelessness (45.83%), dryness of skin (29.17%), fever (16.67%), dyspnea (16.67%), constipation (8.33%), hair loss (8.33%) and diarrhea (4.16%). Score-wise distribution of enrolled patients complaining pain on Wong-Baker FACES Pain Rating Scale score between ‘6’ and ‘8’ BT while after treatment (AT) no patients had score above ‘6’ [Tables 2-4].

Before treatment, OPA score of 87.5% and 12.5% patient’s was ‘3’ and ‘2’ respectively while AT 95.83% patients had OPA score ‘1’ [Table 5].

On NPS, BT assessment, patients showed ‘pain score >5’ on parameters like intensity (91.68%), sharpness (70.84%), hot (20.84%), dull (79.17%), cold (4.17%), sensitive (91.66%), itchy (20.84%), unpleasant (95.83%), deep (87.49%) and surface (50%) types of pain which was reduced below ‘5’ in AT assessment in 100% patients [Table 6].

On HADS, at BT, in anxiety assessment; borderline abnormal and abnormal score was shown by 16.67% and 62.5% patients respectively which reduced up to 16.67% and 4.17% respectively AT. Borderline abnormal score of depression was reflected in 33.33% patients and abnormal score was detected in 50% patients which was reduced to 25% and 16.67% AT respectively [Table 3].

**Table 2: Effect of Shodhita Bhanga therapy on Wong-Baker FACES Pain Rating Scale**

| Scale                   | Time of assessment | Score (% of patients), n=24 |       |      |       |      |      |
|-------------------------|--------------------|-----------------------------|-------|------|-------|------|------|
|                         |                    | 0                           | 2     | 4    | 6     | 8    | 10   |
| Wong-Baker              | BT                 | 0                           | 0     | 4.17 | 20.83 | 62.5 | 12.5 |
| FACES Pain Rating Scale | AT                 | 41.67                       | 54.17 | 4.17 | 0     | 0    | 0    |

BT: Before treatment, AT: After treatment

**Table 3: Effect of Shodhita Bhanga therapy on Hospital Anxiety and Depression Scale**

| Parameter         | Time of assessment | Normal (0-7) (%) | Borderline abnormal (8-11) (%) | Abnormal (12-21) (%) |
|-------------------|--------------------|------------------|--------------------------------|----------------------|
| Anxiety (n=19)    | BT                 | 20.83            | 16.67                          | 62.5                 |
|                   | AT                 | 79.17            | 16.67                          | 4.17                 |
| Depression (n=20) | BT                 | 16.67            | 33.33                          | 50                   |
|                   | AT                 | 45.83            | 25                             | 16.67                |

BT: Before treatment, AT: After treatment

Before treatment, patient’s showed scoring of severity of associated symptoms like *Agnimandya* (Loss of appetite) (41.67%; ‘3’), *Hrillasa* (Nausea) (20.83%; ‘2’), *Aruchi* (Tastelessness) (45.83%; ‘4’), *Atisara* (diarrhoea) (4.17%; ‘3’), *Vibandha* (Constipation) (8.33%; ‘1’), *Daurbalya* (weakness) (29.17%; ‘1’ and ‘3’), *Twakrukshata* (Dryness of skin) (28.57% ‘2’, 71.43% ‘1’), *Keshapatana* (Hair fall) (8.33%; ‘2’), *Jwara* (Fever) (16.67%; ‘1’), *Shrama* (Exhaustion) (29.17%; ‘1,’ 16.67% ‘2’ and 16.67% ‘3’) and *Shwasa* (Dyspnea) (16.67% ‘1’). AT the scoring changes were found as loss of appetite (8.33; ‘1’), *Hrillasa* (Nausea) (20.83%; ‘0’), *Aruchi* (Tastelessness) (41.67%; ‘0’), *Atisara* (diarrhoea) (4.17; ‘1’), *Daurbalya* (weakness) (37.5; ‘1’), *Twakrukshata* (Dryness of skin) (71.43; ‘0’), *Keshapatana* (Hair fall) (4.17; ‘1’), *Jwara* (Fever) (16.67%; ‘0’), *Shrama* (Exhaustion) (37.5%; ‘1’) and *Shwasa* (Dyspnea) (8.33%; ‘0’) [Table 4].

### Performance status

Before treatment, scorings of ECOG scale were found in 4.17% (4), 4.17% (3), 20.83% (2), 54.17% (1) and 16.67% (0). AT, ECOG score of patients was reflected as 4.17% (4), 4.17% (2), 75% (1) and 16.67% (0) [Table 7]. BT, Karnofsky score was found as 25% (90), 37.5% (80), 8.33% (70), 12.5% (60), 8.33% (50) and 8.33% (40). AT, it was reflected as 66.67% (90), 20.83% (80), 4.17% (70), 4.17% (60), and 4.17% (40) [Table 8].

### Drug compliance

Duly signed ‘drug compliance form’ showing records of per week consumption of total capsules by each patient was collected during follow-up.

### Effect of therapy

#### Assessment of percentage difference in relief per week Pain

Fifty percent relief was observed between 2<sup>nd</sup> and 3<sup>rd</sup> weeks of trial period on FACES scale and NPS while between 3<sup>rd</sup> and 4<sup>th</sup> weeks on OPA scale. After completion of trial, 84.10% relief was found on FACES scale and OPA scale. 100% relief was found in cold pain while 92.02%, 74.79%, 79.3%, 78.38% and 66.64% relief was observed in itchy, intensity, unpleasant, deep and hot type of pain respectively as compared to initial status of pain score. TD relieved pain in 8.33%, 16.67% and 33.33% of patients at the end of first, second and third week respectively thus in to 58.33% of patients were relieved from pain while 46.67% patients still complained pain but of reduced intensity [Table 9].

### Associated symptoms

Patients suffering from fever got relief during 2<sup>nd</sup> week. Fifty percent relief in symptoms such as loss of appetite, nausea and insomnia was achieved within a week while in tastelessness, diarrhea, dryness of skin, fatigue and dyspnea; relief was achieved within 2 to 3 weeks. AT, relief found in loss of appetite, tastelessness, insomnia and nausea was 94.87%, 90.91%, 90.91% and 78.57% respectively. More than 75% relief was found in diarrhea and fatigue while 50% relief was found in

**Table 4: Effect of Shodhita Bhanga therapy on associated complaints**

| Associated symptom             | n  | Score | Time of assessment |                 |
|--------------------------------|----|-------|--------------------|-----------------|
|                                |    |       | Before treatment   | After treatment |
| Daurbalya (Fatigue)            | 17 | 0     | 0                  | 29.17           |
|                                |    | 1     | 29.17              | 37.5            |
|                                |    | 2     | 8.33               | 4.17            |
|                                |    | 3     | 29.17              | 0               |
|                                |    | 4     | 4.17               | 4.17            |
| Shrama (Exhaustion)            | 15 | 0     | 0                  | 20.83           |
|                                |    | 1     | 29.17              | 37.5            |
|                                |    | 2     | 16.67              | 20.84           |
| Agnimandya (Loss of appetite)  | 13 | 0     | 0                  | 0               |
|                                |    | 1     | 0                  | 8.33            |
|                                |    | 2     | 12.5               | 0               |
| Nidralpata (Insomnia)          | 11 | 0     | 0                  | 45.84           |
|                                |    | 1     | 0                  | 0               |
|                                |    | 2     | 0                  | 0               |
| Aruchi (Tastelessness)         | 11 | 0     | 45.84              | 0               |
|                                |    | 1     | 0                  | 41.67           |
|                                |    | 2     | 0                  | 0               |
| Hrillasa (Nausea)              | 7  | 0     | 0                  | 0               |
|                                |    | 1     | 8.33               | 4.67            |
|                                |    | 2     | 20.83              | 0               |
|                                |    | 3     | 0                  | 0               |
|                                |    | 4     | 0                  | 0               |
| Twakrukshata (Dryness of skin) | 7  | 0     | 0                  | 71.43           |
|                                |    | 1     | 71.43              | 28.57           |
|                                |    | 2     | 28.57              | 0               |
|                                |    | 3     | 0                  | 0               |
| Jwara (Fever)                  | 4  | 0     | 0                  | 16.67           |
|                                |    | 1     | 16.67              | 0               |
|                                |    | 2     | 0                  | 0               |
| Shwasa (Dyspnea)               | 4  | 0     | 8.33               | 8.33            |
|                                |    | 1     | 16.67              | 4.17            |
|                                |    | 2     | 0                  | 0               |
| Vibandha (Constipation)        | 2  | 0     | 0                  | 0               |
|                                |    | 1     | 8.33               | 0               |
|                                |    | 2     | 0                  | 0               |
|                                |    | 3     | 0                  | 0               |
| Keshapatana (Hair fall)        | 2  | 0     | 0                  | 0               |
|                                |    | 1     | 0                  | 4.17            |
|                                |    | 2     | 8.33               | 4.17            |
|                                |    | 3     | 0                  | 0               |
|                                |    | 4     | 0                  | 0               |

Contd...

**Table 4: Contd...**

| Associated symptom  | n | Score | Time of assessment |                 |
|---------------------|---|-------|--------------------|-----------------|
|                     |   |       | Before treatment   | After treatment |
| Atisara (Diarrhoea) | 1 | 0     | 0                  | 0               |
|                     |   | 1     | 0                  | 4.17            |
|                     |   | 2     | 0                  | 0               |
|                     |   | 3     | 4.17               | 0               |
|                     |   | 4     | 0                  | 0               |

n: Number of patients suffering

**Table 5: Effect of Shodhita Bhanga therapy on Objective Pain Assessment scale**

| Time of assessment   | Score |      |      |
|----------------------|-------|------|------|
|                      | 1     | 2    | 3    |
| Before treatment (%) | 0     | 12.5 | 87.5 |
| After treatment (%)  | 95.83 | 4.17 | 0    |

general debility after the completion of trial [Table 10].

### Statistical significance and overall effect of therapy Pain

Statistically reduction in pain was analyzed on FACES pain scale ( $P < 0.05$ ), OPA scale ( $P < 0.05$ ) and NPS. ( $P < 0.001$ ) [Table 9] during and AT with TD except in two patient's where analgesic was used as a rescue medicine. 'Complete remission' was found in 41.67% patients while 'marked improvement' was found in 54.17% patients and 'moderate improvement' was found in 4.17% patient on cancer pain.

### Pain and associated complaints

Statistically significant result was obtained in loss of appetite, nausea, tastelessness, general debility, dryness of skin, fever, fatigue and insomnia [Table 10]. No significant relief was found in diarrhea and hair loss. Diarrhea was presented due to metastatic carcinoma of rectum and hair loss was due to side effect of chemotherapy. However, TD has not created any negative impact on respective symptoms.

'Complete remission' was found in 66.67% of patients while 'marked improvement' was observed in 33.33% of patients when pain and associated symptoms were assessed together.

### Anxiety and depression

Statistically significant reduction in anxiety and depression was found AT on HADS assessment ( $P < 0.001$ ) [Table 11].

### Quality of life

Statistically significant improvement was found on FACT-G scale except on social well-being parameter.[Table 11]. Social well-being parameter consists questionnaire of personalized relationship aspects influencing patients mind and eventually health. TD reported for creating positive impact on patient's psyche,<sup>[6]</sup> but during this trial period, score of social well-being parameter was unchanged.

**Table 6: Effect of Shodhita Bhanga therapy on Neuropathic Pain Scale**

| Symptom    | TOA | Score (%) |       |       |       |      |       |       |       |       |       |      |
|------------|-----|-----------|-------|-------|-------|------|-------|-------|-------|-------|-------|------|
|            |     | 0         | 1     | 2     | 3     | 4    | 5     | 6     | 7     | 8     | 9     | 10   |
| Intensity  | BT  | 0         | 0     | 0     | 4.17  | 4.17 | 0     | 4.17  | 4.17  | 41.67 | 37.5  | 4.17 |
|            | AT  | 4.17      | 37.5  | 25    | 25    | 8.33 | 0     | 0     | 0     | 0     | 0     | 0    |
| Sharpness  | BT  | 25        | 0     | 4.17  | 0     | 0    | 16.67 | 12.5  | 12.5  | 12.5  | 12.5  | 4.17 |
|            | AT  | 54.17     | 16.67 | 16.67 | 12.5  | 0    | 0     | 0     | 0     | 0     | 0     | 0    |
| Hot        | BT  | 66.67     | 0     | 0     | 8.33  | 0    | 8.33  | 4.17  | 4.17  | 4.17  | 0     | 0    |
|            | AT  | 83.33     | 4.17  | 4.17  | 0     | 8.33 | 0     | 0     | 0     | 0     | 0     | 0    |
| Dull       | BT  | 8.33      | 0     | 4.17  | 0     | 12.5 | 8.33  | 16.67 | 8.33  | 29.17 | 12.5  | 4.17 |
|            | AT  | 29.17     | 45.83 | 20.83 | 4.17  | 0    | 0     | 0     | 0     | 0     | 0     | 0    |
| Cold       | BT  | 91.67     | 4.17  | 0     | 0     | 0    | 0     | 0     | 0     | 4.17  | 0     | 0    |
|            | AT  | 95.83     | 4.17  | 0     | 0     | 0    | 0     | 0     | 0     | 0     | 0     | 0    |
| Sensitive  | BT  | 4.17      | 0     | 0     | 4.17  | 0    | 4.17  | 8.33  | 8.33  | 37.5  | 20.83 | 12.5 |
|            | AT  | 20.83     | 37.5  | 29.17 | 4.17  | 8.33 | 0     | 0     | 0     | 0     | 0     | 0    |
| Itchy      | BT  | 62.5      | 4.17  | 0     | 4.17  | 8.33 | 4.17  | 0     | 8.33  | 4.17  | 0     | 4.17 |
|            | AT  | 83.33     | 16.67 | 0     | 0     | 0    | 0     | 0     | 0     | 0     | 0     | 0    |
| Unpleasant | BT  | 4.17      | 0     | 0     | 0     | 0    | 4.17  | 0     | 8.33  | 37.5  | 33.33 | 12.5 |
|            | AT  | 16.67     | 29.17 | 25    | 16.67 | 8.33 | 0     | 0     | 0     | 0     | 0     | 0    |
| Deep       | BT  | 0         | 0     | 0     | 0     | 12.5 | 8.33  | 8.33  | 20.83 | 25    | 25    | 0    |
|            | AT  | 16.67     | 45.8  | 16.67 | 16.67 | 4.17 | 0     | 0     | 0     | 0     | 0     | 0    |
| Surface    | BT  | 16.67     | 0     | 20.83 | 4.17  | 8.33 | 16.67 | 12.5  | 8.33  | 8.33  | 0     | 4.17 |
|            | AT  | 50        | 41.67 | 4.17  | 0     | 4.17 | 0     | 0     | 0     | 0     | 0     | 0    |

BT: Before treatment, AT: After treatment, TOA: Time of assessment

**Table 7: Effect of Shodhita Bhanga therapy on eastern cooperative oncology group performance score**

| TOA   | Score % |       |       |      |      |   |
|-------|---------|-------|-------|------|------|---|
|       | 0       | 1     | 2     | 3    | 4    | 5 |
| BT(%) | 16.67   | 54.17 | 20.83 | 4.17 | 4.17 | 0 |
| AT(%) | 16.67   | 75    | 4.17  | 0    | 4.17 | 0 |

BT: Before treatment, AT: After treatment, TOA: Time of assessment

**Table 8: Effect of Shodhita Bhanga therapy on Karnofsky score**

| TOA   | Score (%) |    |    |    |      |      |      |      |       |       |     |
|-------|-----------|----|----|----|------|------|------|------|-------|-------|-----|
|       | 0         | 10 | 20 | 30 | 40   | 50   | 60   | 70   | 80    | 90    | 100 |
| BT(%) | 0         | 0  | 0  | 0  | 8.33 | 8.33 | 12.5 | 8.33 | 37.5  | 25    | 0   |
| AT(%) | 0         | 0  | 0  | 0  | 4.17 | 0    | 4.17 | 4.17 | 20.83 | 66.67 | 0   |

BT: Before treatment, AT: After treatment, TOA: Time of assessment

### Performance status

Significant improvement in ECOG ( $P < 0.05$ ) and Karnofsky score ( $P < 0.01$ ) was found. Thus, TD helps in improving performance status QOL in cancer patients [Table 10].

### Adverse drug reaction and Cannabis withdrawal scale

No ADR were noted during the trial period. No withdrawal symptoms were noted after completion of trial. Precautions had been taken while prescribing TD for Pitta predominant Prakriti (constitution) patients and those who were reported to have chronic addiction(s) of any form. Patients ( $n=1$ ) who

reported burning sensation after TD administration were dropped out from trial.

## Discussion

Prevalence of cancer and associated symptoms did not find parallel with any studied parameter of demographic data [Table 1].

Fifty percent relief was found on all the three scales used for assessment of pain within 2–3 weeks of trial period. Relief on pain scales was statistically significant when compared to baseline score [Table 9]. *Bhanga*; due to its *Ushna*<sup>[24]</sup> (Hot) *Veerya* (Potency) helps in reliving *Sheeta* (Cold) completely as excess *Sheeta Guna* (Property) alleviates *Vata* and hence increases pain.<sup>[25]</sup> Being *Iyavayi*<sup>[24]</sup> (Potent in action) and analgesic in nature, drug helps in instant pain reduction. Due to potency of creating pleasurable effects, it helps in achieving feeling of accomplishment of mind's objects by creating state of euphoria thus, helps in reducing unpleasant pain. Hot pain was relived less as compared to other parameters, may be due to hot potency and acidic nature of drug.<sup>[24]</sup> Recent researches reports significant analgesic activity of Cannabis in cancer pain is due to presence of phytoconstituents like tetra-hydrocannabinol (THC) and Cannabidiol (CBD).<sup>[26-29]</sup> Water-wash processed Cannabis contains 65% THC and low traces of CDB in comparison with unpurified one.<sup>[6]</sup>

### Associated symptoms

Cancer patients often experience cluster of symptoms, which can independently predict changes in patient's function,

**Table 9: Assessment of percentage difference in relief per week and statistical significance on pain**

| Interval                     | n  | Percentage relief during treatment period |            |            | AT    | Avg. 50% relief | Statistical significance (AT and BT) |        |          |
|------------------------------|----|---|------------|------------|-------|-----------------|--------------------------------------|--------|----------|
|                              |    | BT-1 week                                 | BT-2 weeks | BT-3 weeks |       |                 | BT-AT                                | Week   | Mean±SEM |
| Scale                        |    |   |            |            |       |                 |                                      |        |          |
| Wong-Baker FACES Pain Rating | 24 | 26.39                                     | 48.54      | 74.10      | 84.10 | 2-3             | 6.42±0.32                            | 20.176 | <0.001   |
| Objective Pain Assessment    | 24 | 26.39                                     | 48.54      | 74.10      | 84.10 | 2-3             | 1.83±0.08                            | 23.592 | <0.001   |
| Neuropathic Pain Scale       |    |   |            |            |       |                 |                                      |        |          |
| Intensity                    | 24 | 26.37                                     | 42.79      | 62.54      | 74.79 | 2-3             | 6.00±0.36                            | 16.849 | <0.001   |
| Hot                          | 7  | 38.11                                     | 38.11      | 69.68      | 66.64 | 2-3             | 1.08±1.08                            | 2.522  | 0.019    |
| Dull                         | 22 | 25.5                                      | 47.98      | 48.74      | 82.45 | 2-3             | 5.21±0.47                            | 11.081 | <0.001   |
| Cold                         | 2  | 50  | 50         | 100        | 100   | At 2            | 0.33±0.34                            | 0.984  | <0.001   |
| Sensitive                    | 23 | 25.67                                     | 44.18      | 65.99      | 80.32 | 2-3             | 6.04±0.46                            | 13.015 | <0.001   |
| Itchy                        | 9  | 92.02                                     | 77.29      | 84.6       | 92.02 | At 1            | 1.88±0.60                            | 3.110  | 0.005    |
| Unpleasant                   | 9  | 23.48                                     | 43.95      | 75.28      | 79.3  | 2-3             | 6.58±0.35                            | 18.780 | <0.001   |
| Deep                         | 24 | 32.91                                     | 45.2       | 68.52      | 78.38 | 2-3             | 3.50±0.51                            | 6.806  | <0.001   |
| Surface                      | 20 | 33.33                                     | 59.83      | 66.34      | 85.98 | At 2            | 3.46±0.50                            | 6.918  | <0.001   |

P<0.05, P<0.02, P<0.01, P<0.001 when compared with initial value (paired ttest).<sup>[18]</sup> SEM: Standard error of mean, BT: Before treatment, AT: After treatment

**Table 10: Assessment of percentage difference in relief per week and statistical significance on associated symptoms**

| Symptoms                              | n  | Percentage relief during treatment period |            |            |       | 50% relief | Statistical significance (AT and BT) |          |        |
|---------------------------------------|----|---|------------|------------|-------|------------|--------------------------------------|----------|--------|
|                                       |    | BT-1 week                                 | BT-2 weeks | BT-3 weeks | BT-AT |            | In week                              | Mean±SEM | t      |
| <i>Daurbalya</i> (weakness)           | 17 | 18.63                                     | 25.49      | 42.16      | 50    | 4          | 0.83±0.21                            | 3.890    | <0.001 |
| <i>Shrama</i> (Exhaustion)            | 15 | 22.22                                     | 37.79      | 55.56      | 65.56 | 2-3        | 0.63±0.15                            | 4.307    | <0.001 |
| <i>Agnimandya</i> (Loss of appetite)  | 13 | 50  | 67.95      | 85.90      | 94.87 | 1          | 1.42±0.28                            | 5.027    | <0.001 |
| <i>Nidralpata</i> (Insomnia)          | 11 | 53.03                                     | 83.33      | 90.91      | 90.91 | 1          | 0.17±0.08                            | 2.145    | 0.043  |
| <i>Aruchi</i> (Tastelessness)         | 11 | 0   | 34.09      | 84.09      | 90.91 | 2-3        | 0.42±0.16                            | 2.632    | 0.015  |
| <i>Hrillasa</i> (Nausea)              | 7  | 57.14                                     | 71.43      | 85.71      | 78.57 | 1          | 1.67±0.41                            | 4.053    | <0.001 |
| <i>Twakrukshata</i> (Dryness of skin) | 7  | 14.29                                     | 28.57      | 57.14      | 50    | 2-3        | 0.25±0.09                            | 2.769    | 0.011  |
| <i>Jwara</i> (Fever)                  | 4  | 75  | 100        | 100        | 100   | 1          | 0.17±0.08                            | 2.145    | 0.043  |
| <i>Shwasa</i> (Dyspnea)               | 4  | 0   | 75         | 75         | 100   | 2          | 0.17±0.08                            | 0.08     | 0.043  |
| <i>Vibandha</i> (Constipation)        | 2  | 8.33                                      | 8.33       | 100        | 100   | 3          | 0.08±0.058                           | 1.446    | 0.162  |
| <i>Keshapatana</i> (Hair fall)        | 2  | 0   | 0          | 25         | 25    | -          | 0.04±0.04                            | 1.000    | 0.328  |
| <i>Atisara</i> (diarrhoea)            | 1  | 33.33                                     | 33.33      | 66.67      | 66.67 | 2-3        | 0.08±0.08                            | 1.000    | 0.328  |

P<0.05, P<0.02, P<0.01, P<0.001 when compared with initial value (paired ttest). SEM: Standard error of mean, BT: Before treatment, AT: After treatment, n: Number of patients suffering

treatment failures and post-therapeutic outcomes.<sup>[30]</sup> *Bhanga* being antipyretic<sup>[6]</sup> reduces fever effectively. Statistically significant effect was obtained in symptoms like loss of appetite, tastelessness, nausea, general debility, dryness of skin, fever, fatigue and dyspnea. More than 90% relief was found in loss of appetite, tastelessness and insomnia. After

administration of TD, 50% relief was achieved within seven days in symptoms like loss of appetite, nausea, fever and insomnia while it took four weeks for improvement in fatigue symptom.

Anti-pyretic action of *Bhanga* is due to its *Tikta* (Bitter) *Rasa* (Taste) and *Swedajanana* (hyperhidrosis) nature.<sup>[31]</sup>

**Table 11: Statistical significance for anxiety, depression, quality of life and performance status on respective scales**

| Parameter/scale (n=24)   | Mean±SEM     | SD     | t     | P      |
|--|--------------|--------|-------|--------|
| Anxiety and depression (Hospital Anxiety and Depression Scale) |              |        |       |        |
| Anxiety  | 7.167±0.996  | 4.878  | 7.197 | <0.001 |
| Depression   | 4.292±0.797  | 3.906  | 5.382 | <0.001 |
| QOL (FACT-G scale)   |              |        |       |        |
| Physical well being  | 8.208±0.849  | 4.160  | 9.667 | <0.001 |
| Social   | 0.0417±0.185 | 0.908  | 0.225 | 0.824  |
| Emotional  | 3.458±1.077  | 5.275  | 3.212 | 0.004  |
| Functional   | 3.250±0.615  | 3.011  | 5.288 | <0.001 |
| Performance status   |              |        |       |        |
| ECOG   | 0.250±0.109  | 0.532  | 2.304 | 0.031  |
| Karnofsky  | 11.25±3.47   | 17.020 | 3.238 | 0.004  |

$P < 0.05$ ,  $P < 0.02$ ,  $P < 0.01$ ,  $P < 0.001$  when compared with initial value (Paired t test). ECOG: Eastern Cooperative Oncology Group, QOL: Quality of life

*Bhanga* imparts *Deepana* (Appetizer), *Pachana* (Digestive) action thus improves loss of appetite, fever, nausea. Due to *Grahi* (Withholds secretions) action; it helps to reduce diarrheal frequency. Being *Balya* (tonic) in nature, it helps in replenishment of *Dhatu* (Body elements) and decreases fatigue.<sup>[6]</sup> According to Ayurveda, *Dhatuparinamana* (Formation of new body constituents/elements) is a sustainable process and takes time of whole month.<sup>[32,33]</sup> Thus, achieving 50% result in fatigue within a month; in patients suffering from cancer; can be considered satisfactory as in case of cancer; patients already gets deteriorated by the disease and its treatment modalities like chemotherapy and radiation.

*Cannabis* is well established medicine for chemotherapy induced nausea and vomiting,<sup>[34,35]</sup> loss appetite, weight loss, pain, depression<sup>[36]</sup> pain with depression, anxiety,<sup>[37]</sup> sleep disorders,<sup>[38-41]</sup> asthma<sup>[42]</sup> and diarrhea<sup>[43]</sup> due to its constituents like THC<sup>[44-46]</sup> and nabilone.<sup>[47-52]</sup>

### Anxiety and depression

Anxiety and depression, commonly co-exist in cancer patients.<sup>[53]</sup> TD showed significant reduction in complaint of anxiety and depression. *Bhanga* creates pleasure and pleasantness, thus; calms patient. Being *Medhya* (memory enhancer) and *Uttejaka* (Stimulant) in nature helps to improve intellect<sup>[6,24]</sup> and alertness of mind respectively.<sup>[54]</sup>

Clinical researches report effectiveness of constituents of *Cannabis* such as nabilone<sup>[36,55,56]</sup> and cannabidiol<sup>[53,54]</sup> for the management of both anxiety and depression simultaneously.<sup>[36]</sup>

### Quality of life

Statistically significant improvement in FACT-G scale's parameters confirms the processed herbal form of *Cannabis* possess role in improving QOL in cancer patients by combating multiple symptoms, similarly like its extract.<sup>[57,58]</sup> [Table 11]. Impact of TD on social behaviour is difficult to co-relate from this study. Clinical researches report, analgesic potential and

improvement of QOL by *Cannabis* is due to its constituent nabilone.<sup>[59,60]</sup>

### Performance status

Disease cancer has negative impact on all systems of body. TD has showed significant improvement in performance status, i.e., functioning status of a patient. *Cannabis* is well reported for aphrodisiac, adaptogenic and immune-modular actions.<sup>[61]</sup> It helps in nourishing and improvement of body tissue and immunity. *Cannabis* being appetizer, digestive, tonic, antipyretic, analgesic, aphrodisiac, adaptogen, quick acting, memory tonic etc., helps in skirmishing pain along with associated cluster of symptoms which eventually helps in improving QOL in patients.

Use of *Cannabis* helps to reduce consumption of opioids.<sup>[62]</sup> Clinically it is proved effective as adjunctive of morphine and found helpful in decreasing morphine induced side effects.<sup>[12]</sup> Still, when administered in unprocessed form *Cannabis* has risk of habit formation and other cognitive impairments.<sup>[63]</sup> The fundamental behind purification of *Cannabis* is to reduce its ill effects.<sup>[8]</sup> With consumption of processed *Cannabis* for a month, no withdrawal symptoms was noted, thus, proves a promising drug in the field of palliative oncology care cancer.

### Conclusion

Administration of *Jalaprakshalana Shodhita Bhanga* (water-wash processed *Cannabis*) leaves powder in dose of 250 mg thrice a day with 50 ml of cow's milk and 4 g sugar as an adjuvant, for a period of 1 month; significantly relieves pain, anxiety and depression of cancer patients without creating any major side effects, dependency and withdrawal symptoms. Processed *Cannabis* is significantly effective for improvement in QOL of a cancer patient.

### Acknowledgment

The author would like to thank Director of IPGT and RA, GAU, Jamnagar and RRAPodar, CARIC, CCRAS, Worli, Mumbai for providing technical support. Legal drug dealer from Haridwar, Uttarakhand and Excise department, Jamnagar, Government of Gujarat; for their help in procurement of drug.

### Financial support and sponsorship

Financial support was given by IPGT and RA, Gujarat Ayurved University, Jamnagar for conducting this research as a part of PhD research project of Dravyaguna department.

### Conflicts of interest

There are no conflicts of interest.

### References

- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. *CA Cancer J Clin* 2004;54:8-29.
- Valdimarsdottir U, Helgason AR, Fürst CJ, Adolfsson J, Steineck G. The unrecognised cost of cancer patients' unrelieved symptoms: A nationwide follow-up of their surviving partners. *Br J Cancer* 2002;86:1540-5.
- Nersesyan H, Slavin KV. Current approach to cancer pain management:



- Availability and implications of different treatment options. *Ther Clin Risk Manag* 2007;3:381-400.
4. Noble B, Clark D, Meldrum M, ten Have H, Seymour J, Winslow M, *et al.* The measurement of pain, 1945-2000. *J Pain Symptom Manage* 2005;29:14-21.
  5. Ahmedzai S. New approaches to pain control in patients with cancer. *Eur J Cancer* 1997;33 Suppl 6:S8-14.
  6. Tavhare SD. Thesis (registration 463), A Study on Impact of Shodhana on phyto-Pharmacological Properties and Biological Actions of *Bhanga* (*Cannabis sativa* Linn.) Leaf, Department of Dravyaguna, Published by Institute for Post-Graduate Teaching and Research in Ayurveda. Jamnagar: Gujarat Ayurved University; April, 2019.
  7. Sharma S, editor. *Rasatrangini*. Ch. 24, Ver. 396-398. 11<sup>th</sup> ed. Delhi: MotilalaBanarasidas; 1979. p. 720.
  8. Tavhare SD, Acharya R. Exploring the pharmaco-clinical view on *Bhanga* (*Cannabis sativa* Linn.): A classical unfamiliar portrayal. *Int J Pharm Biol Arch* 2017;8:38-57.
  9. Acharya R, *et al.*, *Bhanga* (Vijaya) and its therapeutic use (*Cannabis sativa* Linn.) and its therapeutic importance in Ayurveda: A review, *Journal of Drug Research in AyurvedicSciences*, Vol 1, 2015;1:1-12.
  10. Available from: [https://www.unodc.org/pdf/convention\\_1961\\_en.pdf](https://www.unodc.org/pdf/convention_1961_en.pdf). [Last accessed 2019 on Sep 23].
  11. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: A prospective observational study using propensity scoring. *J Support Oncol* 2008;6:119-24.
  12. Joshi D, Rao GP, editor. *Rasamritamof Yadavaji Trikamaji Acharya*. Appendix 8/8. 1<sup>st</sup> ed. Varanasi: Chaukhamba Sanskrit Bhavan; 1998. p. 287.
  13. Anonymous. *Ayurvedic Formulary of India: Part 2, Part B: Shodhana*. 1<sup>st</sup> ed. Delhi: Department of AYUSH, Government of India, Ministry of Health and family welfare, Department of Indian systems of medicine and homeopathy, The controller of publications, civil lines; 2010. p. 28.
  14. Anonymous, *The Ayurvedic Pharmacopeia of India*. Volume 1, Part-I, edition 1<sup>st</sup>, New Delhi: Govt. of India. Ministry of Health and Family welfare, Department of Indian systems of medicine and homeopathy. 1999. p. 166.
  15. Available from: <http://wongbakerfaces.org/>. [Last accessed on 2019 Sep 06].
  16. National Institutes of Health. *Pain Management. Research Portfolio Online Reporting Tools*. National Institutes of Health; 2015. Available from: <https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=57>. [Last accessed on 2018 Aug 27].
  17. Bradley S, Galer, Mark P, Jensen. Development and preliminary validation of a pain measure specific to neuropathic pain. *Neurology* 1997;48:332-8.
  18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *ActaPsychiatrScand* 1983;67:361-70.
  19. Baghel MS, Rajagopala S. *Guidelines Developed for Clinical Research in Ayurveda*, WHO – DFC Sponsored Project. Published by IPGT and RA. Jamnagar: Gujarat Ayurved University; 2011.
  20. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, *et al.* The functional assessment of cancer therapy scale: Development and validation of the general measure. *J ClinOncol* 1993;11:570-9.
  21. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, *et al.* Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J ClinOncol* 1982;5:649-55.
  22. Allsop DJ, Copeland J, Norberg MM, *et al.* Quantifying the clinical significance of cannabis withdrawal. *PLoS One*. 2012;7(9) [PubMed] [Cross-ref].
  23. Available from: [https://ncss-wpengine.netdna-ssl.com/wp-content/themes/ncss/pdf/Procedures/NCSS/Paired\\_T-Test.pdf](https://ncss-wpengine.netdna-ssl.com/wp-content/themes/ncss/pdf/Procedures/NCSS/Paired_T-Test.pdf). [Last accessed on 2019 Sep 06].
  24. Pandey G.S. Chuneekar K C., editor. *Bhavaprakasha Nighantu of Shri Bhavamishra*. Haritakyadi Varga, Ver. 233-234. Revised edition. Varanasi: Chaukhambha Bharati Academy; 2010. p. 136.
  25. Kunte Anna Moreshwar, Navare Krishnashastri, Shastri Hari, editor. *AstangahridayaofVagbhata*. Ch. 1, Ver. 18. 9<sup>th</sup> edition. Varanasi: Chaukhambha Orientalia; 2005. p. 12.
  26. Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. *J Pain Symptom Manage* 2014;47:166-73.
  27. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *J Pain Symptom Manage* 2013;46:207-18.
  28. Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, *et al.* Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: A randomized, placebo-controlled, graded-dose trial. *J Pain* 2012;13:438-49.
  29. Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, *et al.* Results of a double-blind, randomized, placebo-controlled study of nabiximolsoromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. *J Pain Symptom Manage* 2018;55:179-880.
  30. Fan G, Filipczak L, Chow E. Symptom clusters in cancer patients: A review of the literature. *CurrOncol* 2007;14:173-9.I
  31. Acharya YT, editor. *Charaka Samhita of Agnivesha, Sutra Sthana*. Ch. 26, Ver. 42-45. 1<sup>st</sup> ed. Varanasi: Chaukhamba Sanskrit Sanssthana; 2007. p. 348.
  32. Mitra J, Shivprasad S, editor. *Ashtanga Samgraha of Vriddha Vagbhata, Sharira Sthana*. Ch. 6, Ver. 54. 4<sup>th</sup> ed. Varanasi: Chaukhamba Krishnadas Academy; 2016. p. 318.
  33. Acharya YT, editor. *Sushruta Samhita of Sushruta, Sutra Sthana*. Ch. 14, Ver. 14-15. 1<sup>st</sup> ed. Varanasi: Chaukhamba Surbharati Prakashana; 2003. p. 62.
  34. Doblin RE, Kleiman MA. Marijuana as antiemetic medicine: A survey of oncologists' experiences and attitudes. *J ClinOncol* 1991;9:1314-9.
  35. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, *et al.* Preliminary efficacy and safety of an oromucosal standardized *Cannabis* extract in chemotherapy-induced nausea and vomiting. *Br J ClinPharmacol* 2010;70:656-63.
  36. Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. *J Acquir Immune DeficSyndr* 2004;35:38-45.
  37. Howard J, Anie KA, Holdcroft A, Korn S, Davies SC. Cannabis use in sickle cell disease: A questionnaire study. *Br J Haematol* 2005;131:123-8.
  38. Lake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a Cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)* 2006;45:50-2.
  39. Lynch ME, Clark AJ. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. *J Pain Symptom Manage* 2003;25:496-8.
  40. Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study. *ClinNeuropharmacol* 2014;37:41-4.
  41. Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsy I, *et al.* Safety and efficacy of medical Cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study. *J Alzheimers Dis* 2016;51:15-9.
  42. Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. *Am Rev Respir Dis* 1974;109:420-8.
  43. Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn's disease with Cannabis: An observational study. *Isr Med Assoc J* 2011;13:455-8.
  44. Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, *et al.* Comparison of orally administered Cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-in-cachexia-study-group. *J ClinOncol* 2006;24:3394-400.
  45. Sledziński P, Zeyland J, Słomski R, Nowak A. The current state and future perspectives of cannabinoids in cancer biology. *Cancer Med* 2018;7:765-75.
  46. Wong BS, Camilleri M, Eckert D, Carlson P, Ryks M, Burton D. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol

- effects on colon transit in irritable bowel syndrome-diarrhea. *Neurogastroenterol Motil* 2012;24:358-e169.
47. Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: A double blind study. *Med Oncol Tumor Pharmacother* 1986;3:39-42.
  48. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. Prochlorperazine for refractory emesis induced by cancer chemotherapy. *Cancer Treat Rev* 1982;9 Suppl B: 25-33.
  49. Steele N, Gralla RJ, Braun DW Jr., Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. *Cancer Treat Rep* 1980;64:219-24.
  50. Gong H Jr, Tashkin DP, Calvarese B. Comparison of bronchial effects of nabilone and terbutaline in healthy and asthmatic subjects. *J Clin Pharmacol* 1983;23:127-33.
  51. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: A retrospective evaluation. *J Clin Psychopharmacol* 2014;34:559-64.
  52. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial. *Anesth Analg* 2010;110:604-10.
  53. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, *et al.* Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. *Neuropsychopharmacology* 2011;36:1219-26.
  54. Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, *et al.* Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. *J Psychopharmacol* 2011;25:121-30.
  55. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. *J Clin Pharmacol* 1981;21:377S-82S.
  56. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. Single-dose study of nabilone in anxious volunteers. *J Clin Pharmacol* 1981;21:383S-96S.
  57. Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, *et al.* The effect of medicinal Cannabis on pain and quality-of-life outcomes in chronic pain: A prospective open-label study. *Clin J Pain* 2016;32:1036-43.
  58. Goldenberg M, Reid MW, IsHak WW, Danovitch I. The impact of Cannabis and cannabinoids for medical conditions on health-related quality of life: A systematic review and meta-analysis. *Drug Alcohol Depend* 2017;174:80-90.
  59. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. *J Pain* 2008;9:164-73.
  60. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W, *et al.* Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain. a randomized controlled trial. *Wien Klin Wochenschr* 2006;118:327-35.
  61. Tavhare SD, Acharya R. Bhanga (*Cannabis sativa* L.) as an activity potentiator in ayurvedic classics and Indian alchemy (Rasashastra): A review. *Int J Ayurvedic Med* 2016;7:3.
  62. Meng H, Hanlon JG, Katznelson R, Ghanekar A, McGilvray I, Clarke H. The prescription of medical Cannabis by a transitional pain service to wean a patient with complex pain from opioid use following liver transplantation: A case report. *Can J Anaesth* 2016;63:307-10.
  63. Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med* 2014;370:2219-27.